User login
Mark Boguniewicz, MD, Noreen Nicol, MS, RN, FNP, Kim Kelsay, MD, and Donald YM Leung, MD, PhD
Atopic dermatitis is a common, complex disease that frequently follows a chronic, relapsing course. The disease can impact the quality of life (QOL) of patients and families to a significant degree. Patients and caregivers may focus on unproven triggers at the expense of proper skin care. A multidisciplinary approach is needed to comprehensively evaluate triggers and response to treatment, address confounding factors including sleep disruption, and educate patients and caregivers.
*For a PDF of the full article, click on the link to the left of this introduction.
Mark Boguniewicz, MD, Noreen Nicol, MS, RN, FNP, Kim Kelsay, MD, and Donald YM Leung, MD, PhD
Atopic dermatitis is a common, complex disease that frequently follows a chronic, relapsing course. The disease can impact the quality of life (QOL) of patients and families to a significant degree. Patients and caregivers may focus on unproven triggers at the expense of proper skin care. A multidisciplinary approach is needed to comprehensively evaluate triggers and response to treatment, address confounding factors including sleep disruption, and educate patients and caregivers.
*For a PDF of the full article, click on the link to the left of this introduction.
Mark Boguniewicz, MD, Noreen Nicol, MS, RN, FNP, Kim Kelsay, MD, and Donald YM Leung, MD, PhD
Atopic dermatitis is a common, complex disease that frequently follows a chronic, relapsing course. The disease can impact the quality of life (QOL) of patients and families to a significant degree. Patients and caregivers may focus on unproven triggers at the expense of proper skin care. A multidisciplinary approach is needed to comprehensively evaluate triggers and response to treatment, address confounding factors including sleep disruption, and educate patients and caregivers.
*For a PDF of the full article, click on the link to the left of this introduction.
Recent insights into AD have pointed to the role of abnormalities in the epidermal barrier, although these abnormalities may be caused by both mutations of genes encoding proteins such as filaggrin, as well as modulation of epidermal protein levels by Th2-type cytokines.